1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
3Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Copyright © 2015 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | Total (n=65) | Group I (n=21) | Group II (n=44) | p-value |
---|---|---|---|---|
Age (yr) | 65 (36-76) | 65 (47-76) | 63 (36-75) | 0.365 |
Gender | 1.000a) | |||
Male | 59 (90.8) | 19 (90.5) | 40 (90.9) | |
Female | 6 (9.2) | 2 (9.5) | 4 (9.1) | |
Smoking history | 0.655a) | |||
Yes | 60 (92.3) | 19 (90.5) | 41 (93.2) | |
No | 5 (7.7) | 2 (9.5) | 3 (6.8) | |
FEV1 (L) | 2.44 (0.92-4.26) | 2.41 (1.24-3.35) | 2.47 (0.92-4.26) | 0.411 |
Histology | 0.942 | |||
Squamous cell carcinoma | 39 (60.0) | 13 (61.9) | 26 (59.1) | |
Adenocarcinoma | 22 (33.8) | 7 (33.3) | 15 (34.1) | |
Others | 4 (6.2) | 1 (4.8) | 3 (6.8) | |
Tumor size (cm) | 4.3 (1.0-11.6) | 3.7 (2.0-9.1) | 5.8 (1.0-11.6) | 0.105 |
Clinical T classification | 0.020 | |||
cT1-2 | 41 (63.1) | 9 (42.9) | 32 (72.7) | |
cT3 | 24 (36.9) | 12 (57.1) | 12 (27.3) | |
Extent of N2 disease | 0.052 | |||
Clinically evident-histologic confirmation | 32 (49.2) | 10 (47.6) | 22 (50.0) | |
Clinically evident+histologic confirmation | 28 (43.1) | 7 (33.3) | 21 (47.7) | |
Clinically silent but histologically confirmed | 5 (7.7) | 4 (19.0) | 1 (2.3) | |
Level of N2 disease | 0.952 | |||
Single station | 43 (66.2) | 14 (66.7) | 29 (65.9) | |
Multi-station | 22 (33.8) | 7 (33.3) | 15 (34.1) |
Characteristic | Total (n=65) | Group I (n=21) | Group II (n=44) | p-value |
---|---|---|---|---|
Age (yr) | 65 (36-76) | 65 (47-76) | 63 (36-75) | 0.365 |
Gender | 1.000 |
|||
Male | 59 (90.8) | 19 (90.5) | 40 (90.9) | |
Female | 6 (9.2) | 2 (9.5) | 4 (9.1) | |
Smoking history | 0.655 |
|||
Yes | 60 (92.3) | 19 (90.5) | 41 (93.2) | |
No | 5 (7.7) | 2 (9.5) | 3 (6.8) | |
FEV1 (L) | 2.44 (0.92-4.26) | 2.41 (1.24-3.35) | 2.47 (0.92-4.26) | 0.411 |
Histology | 0.942 | |||
Squamous cell carcinoma | 39 (60.0) | 13 (61.9) | 26 (59.1) | |
Adenocarcinoma | 22 (33.8) | 7 (33.3) | 15 (34.1) | |
Others | 4 (6.2) | 1 (4.8) | 3 (6.8) | |
Tumor size (cm) | 4.3 (1.0-11.6) | 3.7 (2.0-9.1) | 5.8 (1.0-11.6) | 0.105 |
Clinical T classification | 0.020 | |||
cT1-2 | 41 (63.1) | 9 (42.9) | 32 (72.7) | |
cT3 | 24 (36.9) | 12 (57.1) | 12 (27.3) | |
Extent of N2 disease | 0.052 | |||
Clinically evident-histologic confirmation | 32 (49.2) | 10 (47.6) | 22 (50.0) | |
Clinically evident+histologic confirmation | 28 (43.1) | 7 (33.3) | 21 (47.7) | |
Clinically silent but histologically confirmed | 5 (7.7) | 4 (19.0) | 1 (2.3) | |
Level of N2 disease | 0.952 | |||
Single station | 43 (66.2) | 14 (66.7) | 29 (65.9) | |
Multi-station | 22 (33.8) | 7 (33.3) | 15 (34.1) |
Variable | Total (n=65) | Group I (n=21) | Group II (n=44) |
---|---|---|---|
Distant metastasis | 18 (27.7) | 7 (33.3) | 11 (25.0) |
Locoregional progression | 11 (16.9) | 4 (19.0) | 7 (15.9) |
Local | 2 | 1 | 1 |
Regional | 6 | 1 | 5 |
Local and regional | 3 | 2 | 1 |
Both | 5 (7.7) | 1 (4.8) | 4 (9.1) |
Local and distant metastasis | 2 | 1 | 1 |
Regional and distant metastasis | 3 | 0 | 3 |
Total | 34 (52.3) | 12 (57.1) | 22 (50.0) |
Variable | No. | Rates at 2 years |
|||||
---|---|---|---|---|---|---|---|
PFS (%) | p-value | OS (%) | p-value | LRC (%) | p-value | ||
Treatment group | 0.748 | 0.353 | 0.866 | ||||
I | 21 | 44.9 | 53.9 | 77.1 | |||
II | 44 | 46.8 | 48.6 | 73.3 | |||
Gender | 0.831 | 0.057 | 0.597 | ||||
Male | 59 | 45.4 | 47 | 73.1 | |||
Female | 6 | 50 | 83.3 | 83.3 | |||
Age (yr) | 0.158 | 0.172 | 0.089 | ||||
< 60 | 21 | 33.6 | 36.5 | 57.8 | |||
≥ 60 | 44 | 52.5 | 56.6 | 82.2 | |||
Histology | 0.120 | 0.844 | 0.702 | ||||
Squamous cell carcinoma | 39 | 52.2 | 47.5 | 69.1 | |||
Adenocarcinoma | 22 | 40.3 | 52.5 | 80 | |||
Others | 4 | 25 | 75 | 100 | |||
Clinical T | 0.602 | 0.801 | 0.742 | ||||
T1-2 | 41 | 42.9 | 51.1 | 69.2 | |||
T3 | 24 | 50.1 | 48.4 | 81.8 | |||
Multistation N2 | 0.860 | 0.838 | 0.831 | ||||
No | 43 | 43.8 | 50.3 | 73.5 | |||
Yes | 22 | 50.8 | 49.7 | 74.3 | |||
Chemotherapy | 0.028 | 0.040 | 0.237 | ||||
Taxane+platinum | 54 | 37.1 | 45.1 | 64.9 | |||
Cisplatin+etoposide | 11 | 80.8 | 71.6 | 100 | |||
Treatment break | 0.636 | 0.816 | 0.515 | ||||
No | 52 | 46.4 | 49.2 | 74.8 | |||
Yes | 13 | 43.5 | 55.1 | 72 |
Values are presented as median (range) or number (%). FEV1, forced expiratory volume in 1 second. Examined by Fisher exact test.
Values are presented as number (%).
PFS, progression-free survival; OS, overall survival; LRC, locoregional control.